CASE COMMENTS: UNILATERAL PRACTICES – EUROPEAN UNION – RELEVANT MARKET – PRICE – THERAPEUTIC USE

Relevant market: The General Court of the European Union finds that the European Commission made a series of errors in defining a relevant market in the pharmaceutical sector (Servier)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. In a judgment delivered on 12 December 2018, the Court of First Instance of the European Union (the "Court") sanctioned the European Commission (the "Commission") for having committed a series of errors in its analysis of the definition of the relevant market to which perindopril, an angiotensin-converting enzyme ("ACE") inhibitor discovered by the Servier laboratory ("Servier") and intended for the treatment of cardiovascular diseases, belongs. This is one of eight judgments rendered by the Tribunal (Trib. EU, 12 December 2018, Biogaran, Case T-677/14; Teva UK, Case T-679/14; Lupin, Case T-680/14, Mylan Laboratories and Mylan; Krka, Case T-682/14, Krka,

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Nicolas Zacharie, Anne Wachsmann, Relevant market: The General Court of the European Union finds that the European Commission made a series of errors in defining a relevant market in the pharmaceutical sector (Servier), 12 December 2018, Concurrences N° 1-2019, Art. N° 89029, pp. 84-87

Visites 332

All reviews